> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Bone Drugs Panel to Review Lipocine Testosterone NDA
- URL: https://www.fdaweb.com/bone-drugs-panel-to-review-lipocine-testosterone-nda/
- Published: 2017-11-16T12:00:00.000Z
- Updated: 2026-09-14T23:02:17.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140146

*Federal Register* notice: FDA has announced a 1/10/2018 Bone, Reproductive and Urologic Drugs Advisory Committee meeting. Panel members will discuss a Lipocine Inc. NDA for oral testosterone undecanoate capsules, seeking an indication for testosterone replacement in males for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired). To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-11-16/pdf/2017-24832.pdf?ref=fdaweb.com).